Postmenopausal osteoporosis: Fracture consequences and treatment efficacy vary by skeletal site

被引:13
作者
Epstein, S [1 ]
机构
[1] Med Coll Penn & Hahnemann Univ, Sch Med, Philadelphia, PA 19102 USA
关键词
hip fractures; postmenopausal osteoporosis; spinal fractures; treatment of osteoporosis;
D O I
10.1007/BF03339858
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
At least half of all postmenopausal women will experience fractures during their lifetime, and the consequences are often serious, but most women at risk are not receiving adequate treatment. The objective of this paper is to summarize the literature concerning the consequences of osteoporotic fractures, and the effectiveness of pharmacologic agents for preventing fractures and their consequences, emphasizing a systematic, evidence-based summary of treatment results from randomized, controlled trials that were published previously. Osteoporosis is associated with increased risk of fractures at most skeletal sites. Hip fractures have much greater prognostic significance in terms of health than any other single type of fracture. However, symptomatic vertebral fractures and other non-hip fractures also represent enormous morbidity and economic burdens, and signal increased risk of future fractures of all types, including the hip. There is convincing evidence that true bisphosphonates (alendronate and risedronate) reduce the risk of both spine and non-spine fractures. The evidence for reducing hip fracture risk is greater for alendronate, with a consistent similar to 50% reduction in hip fractures across studies. Alendronate has also been demonstrated to maintain quality of life by reducing outcomes such as hospitalization and bed rest related to back pain. Among other agents, raloxifene reduces the risk of vertebral fractures by approximately 30%; the published evidence for most other agents is inconclusive. Osteoporosis should be regarded as seriously as other important chronic disorders such as hypertension and hyperlipidemia. Postmenopausal patients with a high risk of fractures - such as those with prior fractures or osteoporosis as measured by BMD - need to be treated. Although other therapeutic modalities are available, the evidence is most convincing for the bisphosphonates, alendronate; and risedronate. (C)2000, Editrice Kurtis.
引用
收藏
页码:330 / 341
页数:12
相关论文
共 81 条
[1]   THE EFFECTS OF 2-YEAR TREATMENT WITH THE AMINOBISPHOSPHONATE ALENDRONATE ON BONE METABOLISM, BONE HISTOMORPHOMETRY, AND BONE STRENGTH IN OVARIECTOMIZED NONHUMAN-PRIMATES [J].
BALENA, R ;
TOOLAN, BC ;
SHEA, M ;
MARKATOS, A ;
MYERS, ER ;
LEE, SC ;
OPAS, EE ;
SEEDOR, JG ;
KLEIN, H ;
FRANKENFIELD, D ;
QUARTUCCIO, H ;
FIORAVANTI, C ;
CLAIR, J ;
BROWN, E ;
HAYES, WC ;
RODAN, GA .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2577-2586
[2]   Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures [J].
Black, DM ;
Arden, NK ;
Palermo, L ;
Pearson, J ;
Cummings, SR .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (05) :821-828
[3]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[4]   Attitudes to osteoporosis and hormone replacement therapy among elderly women [J].
Brennan, NJ ;
Caplan, GA .
OSTEOPOROSIS INTERNATIONAL, 1999, 9 (02) :139-143
[5]   Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].
Center, JR ;
Nguyen, TV ;
Schneider, D ;
Sambrook, PN ;
Eisman, JA .
LANCET, 1999, 353 (9156) :878-882
[6]   EFFECT OF CALCIUM AND CHOLECALCIFEROL TREATMENT FOR 3 YEARS ON HIP-FRACTURES IN ELDERLY WOMEN [J].
CHAPUY, MC ;
ARLOT, ME ;
DELMAS, PD ;
MEUNIER, PJ .
BRITISH MEDICAL JOURNAL, 1994, 308 (6936) :1081-1082
[7]   COSTS AND HEALTH-EFFECTS OF OSTEOPOROTIC FRACTURES [J].
CHRISCHILLES, E ;
SHIREMAN, T ;
WALLACE, R .
BONE, 1994, 15 (04) :377-386
[8]  
CHRISTIANSEN C, 1991, AM J MED, V90, P107
[9]   QUALITY-OF-LIFE ISSUES IN WOMEN WITH VERTEBRAL FRACTURES DUE TO OSTEOPOROSIS [J].
COOK, DJ ;
GUYATT, GH ;
ADACHI, JD ;
CLIFTON, J ;
GRIFFITH, LE ;
EPSTEIN, RS ;
JUNIPER, EF .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :750-756
[10]   POPULATION-BASED STUDY OF SURVIVAL AFTER OSTEOPOROTIC FRACTURES [J].
COOPER, C ;
ATKINSON, EJ ;
JACOBSEN, SJ ;
OFALLON, WM ;
MELTON, LJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (09) :1001-1005